- The FDA releases black box warning for the drug Ocaliva after the excessive dosing.
- Incorrect dose of Ocaliva for a rare liver disease, increases the risk of liver injury and death. /
- The drug manufacturer, Intercept Pharmaceuticals Inc has released prescribing information for Ocaliva to health care providers.
The liver disease medicine Ocaliva (obeticholic acid) is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death.
Intercept gave healthcare providers prescribing information for Ocaliva and flagged reports of liver failure and deaths. Two weeks later, the FDA released a black box warning.
A black box warning is the strictest warning by the FDA that appears on a prescription drug's label, calling attention to serious or life-threatening risks of a drug.
Ocaliva For Liver Disease
Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC). PBC causes the bile ducts in the liver to become inflamed, damaged and destroyed. This causes bile, a fluid that helps in digestion, to build up in the liver. This build-up damages the liver over time, eventually causing it to lose its ability to function.
The FDA approved obeticholic acid in May 2016 to treat adults with PBC in combination with ursodeoxycholic acid (UDCA) when the latter drug falls short therapeutically, or by itself when adults can't tolerate UDCA.
Ocaliva has been shown to improve a certain blood test that measures liver problems but also has adverse liver-related reactions that may be inconsistent with the patient's extent of disease.
Adverse Symptoms of Ocaliva
- New or worsening fatigue
- Weight loss
- Abdominal pain
- Decreased appetite
- Nausea and vomiting
- Change in behavior or confusion
- Vague symptoms such as anxiety or unease
- Abdominal swelling
- Yellow eyes or skin
- Steatorrhea or Bloody stools